CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade EyePoint Pharmaceuticals, Inc. - EYPT CFD

    Market is not available at the moment

    Market information is presented
    as of 2023-09-21

    • Summary
    Trading Conditions
    Spread -
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    EyePoint Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* N/A
    Open* N/A
    1-Year Change* N/A
    Day's Range* N/A
    52 wk Range 2.19-15.63
    Average Volume (10 days) 601.24K
    Average Volume (3 months) 12.31M
    Market Cap 351.94M
    P/E Ratio -100.00K
    Shares Outstanding 34.98M
    Revenue 37.33M
    EPS -2.83
    Dividend (Yield %) N/A
    Beta 1.35
    Next Earnings Date Oct 31, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    Date Close Change Change (%) Open High Low

    EyePoint Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Tuesday, September 26, 2023

    Time (UTC)

    17:15

    Country

    US

    Event

    EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
    EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

    Forecast

    -

    Previous

    -
    Tuesday, October 10, 2023

    Time (UTC)

    17:45

    Country

    US

    Event

    EyePoint Pharmaceuticals Inc at JonesTrading Healthcare Summit
    EyePoint Pharmaceuticals Inc at JonesTrading Healthcare Summit

    Forecast

    -

    Previous

    -
    Tuesday, October 31, 2023

    Time (UTC)

    12:30

    Country

    US

    Event

    Q3 2023 EyePoint Pharmaceuticals Inc Earnings Release
    Q3 2023 EyePoint Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, February 29, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 EyePoint Pharmaceuticals Inc Earnings Release
    Q4 2023 EyePoint Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 41.404 36.939 34.437 20.365 2.928
    Revenue 41.404 36.939 34.437 20.365 2.928
    Total Operating Expense 142.6 90.15 72.632 72.036 27.487
    Selling/General/Admin. Expenses, Total 60.324 53.078 45.429 47.711 17.075
    Research & Development 49.642 28.5 17.424 15.368 10.412
    Unusual Expense (Income) 22.258 -2.065 1.495 3.81
    Operating Income -101.196 -53.211 -38.195 -51.671 -24.559
    Interest Income (Expense), Net Non-Operating -1.058 -5.206 -7.199 -5.122 -20.161
    Net Income Before Taxes -102.254 -58.417 -45.394 -56.793 -44.72
    Net Income After Taxes -102.254 -58.417 -45.394 -56.793 -44.72
    Net Income Before Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
    Net Income -102.254 -58.417 -45.394 -56.793 -44.72
    Income Available to Common Excl. Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
    Income Available to Common Incl. Extra. Items -102.254 -58.417 -45.394 -56.793 -44.72
    Diluted Net Income -102.254 -58.417 -45.394 -56.793 -44.72
    Diluted Weighted Average Shares 37.317 28.758 12.836 10.4307 8.5057
    Diluted EPS Excluding Extraordinary Items -2.74015 -2.03133 -3.53646 -5.44479 -5.25765
    Diluted Normalized EPS -2.14369 -2.10314 -3.37403 -5.07952 -5.25765
    Total Extraordinary Items
    Dividends per Share - Common Stock Primary Issue 0
    Cost of Revenue, Total 8.326 8.177 5.824 2.687
    Gross Profit 33.078 28.762 28.613 17.678
    Depreciation / Amortization 2.05 2.46 2.46 2.46
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 9.105 7.683 10.533 10.012 11.565
    Revenue 9.105 7.683 10.533 10.012 11.565
    Cost of Revenue, Total 1.792 0.64 3.41 1.405 1.734
    Gross Profit 7.313 7.043 7.123 8.607 9.831
    Total Operating Expense 33.213 29.237 54.268 28.41 30.781
    Selling/General/Admin. Expenses, Total 14.635 15.27 14.411 15.228 15.44
    Research & Development 15.439 13.327 15.543 11.162 12.992
    Depreciation / Amortization 0 0 0.205 0.615 0.615
    Operating Income -24.108 -21.554 -43.735 -18.398 -19.216
    Interest Income (Expense), Net Non-Operating 1.188 0.39 0.283 -0.022 -0.19
    Net Income Before Taxes -22.92 -21.164 -43.452 -18.42 -19.406
    Net Income After Taxes -22.92 -21.164 -43.452 -18.42 -19.406
    Net Income Before Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
    Net Income -22.92 -21.164 -43.452 -18.42 -19.406
    Income Available to Common Excl. Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
    Income Available to Common Incl. Extra. Items -22.92 -21.164 -43.452 -18.42 -19.406
    Diluted Net Income -22.92 -21.164 -43.452 -18.42 -19.406
    Diluted Weighted Average Shares 37.576 37.486 37.353 37.338 37.322
    Diluted EPS Excluding Extraordinary Items -0.60996 -0.56458 -1.16328 -0.49333 -0.51996
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.57412 -0.56458 -0.60913 -0.49333 -0.51996
    Unusual Expense (Income) 1.347 0 20.699 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 172.808 237.745 63.118 41.717 47.601
    Cash and Short Term Investments 144.561 211.558 44.909 22.214 45.261
    Cash & Equivalents 95.633 178.593 44.909 22.214 45.261
    Short Term Investments 48.928 32.965
    Total Receivables, Net 15.503 18.354 9.453 11.368 0.627
    Accounts Receivable - Trade, Net 15.503 18.354 9.453 11.368 0.627
    Prepaid Expenses 9.858 4.217 3.419 5.997 1.434
    Total Assets 180.356 263.372 91.717 72.971 78.168
    Property/Plant/Equipment, Total - Net 7.398 2.728 3.24 3.435 0.288
    Property/Plant/Equipment, Total - Gross 9.505 3.984 4.268 4.274 0.983
    Accumulated Depreciation, Total -2.107 -1.256 -1.028 -0.839 -0.695
    Intangibles, Net 0 22.749 25.209 27.669 30.129
    Other Long Term Assets, Total 0.15 0.15 0.15 0.15 0.15
    Total Current Liabilities 34.537 23.658 14.888 11.52 21.459
    Accounts Payable 5.919 7.385 4.811 4.192 2.64
    Accrued Expenses 16.902 15.067 9.013 7.313 18.789
    Notes Payable/Short Term Debt 10.475 0 0 0 0
    Other Current Liabilities, Total 1.205 1.069 0.945 0.015 0.03
    Total Liabilities 83.988 78.992 73.176 64.641 40.535
    Total Long Term Debt 29.31 36.598 38.048 47.223 17.621
    Other Liabilities, Total 20.141 18.736 20.24 5.898 1.455
    Total Equity 96.368 184.38 18.541 8.33 37.633
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.034 0.034 0.018 0.109 0.095
    Additional Paid-In Capital 766.899 752.602 528.362 472.667 445.192
    Retained Earnings (Accumulated Deficit) -671.351 -569.097 -510.68 -465.286 -408.493
    Other Equity, Total 0.786 0.841 0.841 0.84 0.839
    Total Liabilities & Shareholders’ Equity 180.356 263.372 91.717 72.971 78.168
    Total Common Shares Outstanding 34.0829 33.9058 18.14 10.9417 9.53722
    Long Term Debt 29.31 36.562 37.977 47.223 17.621
    Total Inventory 2.886 3.616 5.337 2.138 0.279
    Current Port. of LT Debt/Capital Leases 0.036 0.137 0.119
    Capital Lease Obligations 0 0.036 0.071
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 146.057 172.808 192.102 205.866 219.629
    Cash and Short Term Investments 122.483 144.561 157.259 171.167 190.784
    Cash & Equivalents 105.765 95.633 75.362 82.134 101.545
    Total Receivables, Net 10.422 15.503 20.876 22.594 19.589
    Accounts Receivable - Trade, Net 10.422 15.503 20.876 22.594 19.589
    Total Inventory 4.071 2.886 3.531 3.254 3.336
    Prepaid Expenses 9.081 9.858 10.436 8.851 5.92
    Total Assets 154.593 180.356 220.49 233.433 244.555
    Property/Plant/Equipment, Total - Net 8.386 7.398 7.334 5.898 2.642
    Property/Plant/Equipment, Total - Gross 9.505 6.589 5.057 2.367
    Accumulated Depreciation, Total -2.107 -0.206 -0.172 -0.138
    Intangibles, Net 0 20.904 21.519 22.134
    Other Long Term Assets, Total 0.15 0.15 0.15 0.15 0.15
    Total Current Liabilities 27.242 34.537 34.256 33.39 31.971
    Accounts Payable 9.453 5.919 6.112 7.058 7.302
    Accrued Expenses 11.239 16.902 16.429 14.613 12.97
    Notes Payable/Short Term Debt 5.295 10.475 10.475 10.475 10.475
    Current Port. of LT Debt/Capital Leases 0.036 0.07 0.105 0.122
    Other Current Liabilities, Total 1.255 1.205 1.17 1.139 1.102
    Total Liabilities 76.203 83.988 84.14 82.067 77.736
    Total Long Term Debt 29.37 29.31 29.251 29.181 29.126
    Long Term Debt 29.37 29.31 29.251 29.181 29.108
    Capital Lease Obligations 0 0 0 0.018
    Other Liabilities, Total 19.591 20.141 20.633 19.496 16.639
    Total Equity 78.39 96.368 136.35 151.366 166.819
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.034 0.034 0.034 0.034 0.034
    Additional Paid-In Capital 770.028 766.899 763.562 760.209 756.07
    Retained Earnings (Accumulated Deficit) -692.515 -671.351 -627.899 -609.479 -590.073
    Other Equity, Total 0.843 0.786 0.653 0.602 0.788
    Total Liabilities & Shareholders’ Equity 154.593 180.356 220.49 233.433 244.555
    Total Common Shares Outstanding 34.3019 34.0829 34.0722 34.0526 34.0471
    Short Term Investments 16.718 48.928 81.897 89.033 89.239
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -102.254 -58.417 -45.394 -56.793 -44.72
    Cash From Operating Activities -65.005 -50.097 -14.435 -56.699 -22.586
    Cash From Operating Activities 0.396 0.311 0.189 0.144 0.097
    Amortization 2.05 2.46 2.46 2.46 1.229
    Non-Cash Items 37.826 7.288 8.174 10.026 21.748
    Cash Taxes Paid
    Changes in Working Capital -3.023 -1.739 20.136 -12.536 -0.94
    Cash From Investing Activities -17.265 -33.121 -0.362 -0.213 -0.132
    Capital Expenditures -2.15 -0.156 -0.362 -0.213 -0.132
    Other Investing Cash Flow Items, Total -15.115 -32.965 0 0
    Cash From Financing Activities -0.69 216.902 37.492 33.864 29.204
    Issuance (Retirement) of Stock, Net 0.395 217.198 50.212 23.041 29.399
    Foreign Exchange Effects 0 0.001 -0.001
    Net Change in Cash -82.96 133.684 22.695 -23.047 6.485
    Cash Interest Paid 2.6 4.846 5.51 4.87 1.241
    Financing Cash Flow Items -3.188 -0.15 -0.918 -19.177 -0.195
    Issuance (Retirement) of Debt, Net 2.103 -0.146 -11.802 30 0
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -21.164 -102.254 -58.802 -40.382 -20.976
    Cash From Operating Activities -16.835 -65.005 -52.417 -39.281 -20.158
    Cash From Operating Activities 0.105 0.396 0.266 0.17 0.081
    Amortization 0 2.05 1.845 1.23 0.615
    Non-Cash Items 2.806 37.826 12.157 9.172 5.146
    Cash Interest Paid 0.74 2.6 1.907 1.349 0.941
    Changes in Working Capital 1.418 -3.023 -7.883 -9.471 -5.024
    Cash From Investing Activities 32.086 -17.265 -50.182 -56.454 -56.442
    Capital Expenditures -0.484 -2.15 -1.565 -0.367 -0.149
    Cash From Financing Activities -5.119 -0.69 -0.632 -0.724 -0.448
    Financing Cash Flow Items -0.169 -3.188 -3.164 -3.138 -2.896
    Issuance (Retirement) of Stock, Net 0.248 0.395 0.395 0.241 0.241
    Issuance (Retirement) of Debt, Net -5.198 2.103 2.137 2.173 2.207
    Net Change in Cash 10.132 -82.96 -103.231 -96.459 -77.048
    Other Investing Cash Flow Items, Total 32.57 -15.115 -48.617 -56.087 -56.293
    Foreign Exchange Effects

    EyePoint Pharmaceuticals, Inc. Company profile

    About Eyepoint Pharmaceuticals Inc

    EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor. EYP-1901 is in Phase I clinical trial and targeting treatment of wet age-related macular degeneration for additional indications in diabetic retinopathy and retinal vein occlusion. DEXYCU is a single-dose treatment for postoperative inflammation following ocular surgery. YUTIQ50 is a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. It is utilizing its core technology platform, Durasert to deliver drugs and biologics to treat chronic diseases.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Eyepoint Pharmaceuticals Inc revenues increased 7% to $36.9M. Net loss increased 29% to $58.4M. Revenues reflect DEXYCU segment increase from $7M to $18.4M, YUTIQ segment increase of 22% to $17M, United States segment increase of 59% to $36M. Higher net loss reflects Research and Development Expense increase of 64% to $26.2M (expense), General and administrative increase of 19% to $20.7M (expense).

    Equity composition

    Common Stock $0.001 Par, 02/11, 60M auth., 20,741,392 issd. Insiders own 11.62%. 8/04 :49,804,381 shs issd @ $1.09each to pSiMedica Ltd on acquisition. 06/08, Name changed from pSivida Limited. 06/08, 1-for-40 reverse stock split.

    Industry: Pharmaceuticals (NEC)

    480 Pleasant St Ste B300
    WATERTOWN
    MASSACHUSETTS 02472-2468
    US

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    XRP/USD

    0.52 Price
    +0.330% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,787.50 Price
    +0.760% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    BTC/USD

    26,630.10 Price
    +0.030% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,597.79 Price
    +0.530% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading